Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Chemoradiotherapy
  • Lymphoma, Large B-Cell, Diffuse
  • Rituximab

abstract

  • RT utilization has decreased following incorporation of Rituximab for first line treatment of DLBCL. RT use is associated with improved OS in both pre- and post-Rituximab eras, suggesting that RT should continue to be used for management of early stage DLBCL, even in the era of Rituximab.

publication date

  • July 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.radonc.2016.05.027

PubMed ID

  • 27373911

Additional Document Info

start page

  • 150

end page

  • 5

volume

  • 120

number

  • 1